Company profile: Imago BioSciences
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical drug development focused on novel medicines for managing proliferative diseases of the bone marrow, translating state-of-the-art science and leveraging the skills and experience of its team and the financial commitment of its investors.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Imago BioSciences
Ayala Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage small molecule therapeutics, including gamma secretase inhibitors that block Notch-pathway activation. Pipeline includes AL101 in Phase 2 for recurrent/metastatic adenoid cystic carcinoma and AL102 in Phase 2/3 for desmoid tumors, with a planned Phase 2 in relapsed/refractory T-cell acute lymphoblastic leukemia. Conducts clinical trials to evaluate safety and efficacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ayala Pharmaceuticals company profile →
GenomeDx
HQ: Canada
Website
- Description: Provider of genomic-based laboratory tests for personalized medicine in cancer care, including the Decipher Prostate Cancer Classifier for independent assessment of tumor aggressiveness, the Decipher GRID genomic expression database in urologic cancer, and genomic testing and a development pipeline focused on creating genomic tests for urologic cancers to aid personalized treatment decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenomeDx company profile →
ProNova Solutions
HQ: United States
Website
- Description: Provider of compact proton therapy systems and project development services for cancer treatment. Offers the ProNova SC360 with pencil beam scanning and cone-beam CT imaging, leveraging superconducting magnet technology in the cyclotron and treatment gantry, and supports design, construction, equipment installation, commissioning, and clinical start-up of proton therapy centers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProNova Solutions company profile →
Biomea Fusion
HQ: United States
Website
- Description: Provider of precision oncology and metabolic disease therapeutics based on novel covalent small molecules, including BMF-219, an oral investigational menin inhibitor for genetically defined cancers (AML, ALL, DLBCL, MM, CLL) and type 2 diabetes by enabling beta-cell proliferation and function; BMF-500, an investigational oral FLT3 inhibitor for AML; and the FUSION System, a platform for designing covalent small molecule therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biomea Fusion company profile →
Cytognos
HQ: Spain
Website
- Description: Provider of flow cytometry solutions for blood cancer diagnosis, minimal residual disease detection, and immune monitoring research. Offers Infinicyt software for multicolor data integration and analysis; EuroFlow 8-color antibody panels; OC515 dye; APC-C750 fluorochrome; and Next Generation Flow immunophenotyping protocols.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cytognos company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Imago BioSciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Imago BioSciences
2.2 - Growth funds investing in similar companies to Imago BioSciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Imago BioSciences
4.2 - Public trading comparable groups for Imago BioSciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →